Oncologist To Present Annual Block Lecture At Ohio State

March 22, 2011

COLUMBUS, Ohio – Dr. Bruce A. Chabner, director clinical research at the Massachusetts General Hospital Cancer Center, has been selected to receive the 18th annual Herbert and Maxine Block Memorial Lectureship Award for Achievement in Cancer. He will visit The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) on March 31 to deliver the Block Lecture.

The award, established by the Block family of Columbus, honors the memory of their parents, Maxine and Herbert J. Block, who both died of cancer. It is given annually to a renowned cancer researcher who is invited to OSUCCC – James to accept the award and deliver the annual Block Lecture.

Chabner, who also is a professor of medicine at Harvard Medical School, will present “Cancer as a Rare Disease: Revolutionizing Drug Development,” at 8 a.m. March 31 in room 518A at The James Cancer Hospital and Solove Research Institute. Media are invited to attend, and Chabner will be available for interviews immediately following his presentation.

Chabner has devoted his clinical and research career to the improvement of patient treatment and the quality of care. As director of the National Cancer Institute’s division of cancer treatment from 1982 to 1995, Chabner used his position to significantly influence drug development and improve the therapy for cancer. During his tenure at both the National Cancer Institute and Harvard Medical School, he has been involved in leading therapeutic advances such as high-dose therapies for lymphoma, colorectal cancer and breast cancer.

A monetary award of $25,000 is associated with the Block Memorial Lectureship, making it one of the largest prizes awarded by an academic institution in the field of cancer. The Block Memorial Lectureship is funded by proceeds of the annual Herbert J. Block Memorial Tournamentre, a golf outing established in 1982 by the Block family of Columbus to honor their father. The next one will be Sept. 12 at the Scioto Country Club.

The lecture is free, but seating is limited. To make a reservation, e-mail Nancy Jones at Nancy.Jones@osumc.edu.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (cancer.osu.edu) is one of only 40 Comprehensive Cancer Centers in the United States designated by the National Cancer Institute. Ranked by U.S. News & World Report among the top cancer hospitals in the nation, The James is the 205-bed adult patient-care component of the cancer program at The Ohio State University. The OSUCCC-James is one of only seven funded programs in the country approved by the NCI to conduct both Phase I and Phase II clinical trials.

# # #

Related Links:

  • Click here for a high-quality photo of Dr. Bruce Chabner

Eileen Scahill
Medical Center Public Affairs and Media Relations

Contact Media Staff

Amanda Harper

Director of Media Relations

614-685-5420 (direct)

614-293-3737 (main)


Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.


If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

Ohio State, ORIEN Could Play Role in Vice President's Cancer Moonshot Initiative

ORIEN, a network formed by Ohio State and Moffitt Cancer Center, could play an important role in the White House Cancer Moonshot initiative by facilitating the sharing of important data.

Ohio State: An Exceptional Comprehensive Cancer Center Helping Cancer Patients

Director of the OSUCCC Dr. Michael Caligiuri discusses the importance of being an NCI-designated comprehensive cancer center, where research flourishes and the best scientists and physicians want to work.

A Fireside Chat with The James CEO Dr. Michael Caligiuri

Dr. Caligiuri hosts a chat where he talked about the “exceptional” rating The James recently received from the NCI, advances in immunology & how ORIEN could play a role in the cancer “moonshot” program.